Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from Analysts at Maxim Group

Maxim Group assumed coverage on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report released on Friday morning, Marketbeat reports. The firm issued a buy rating and a $10.00 price target on the stock.

Several other equities analysts also recently commented on ANIX. D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Wednesday, January 22nd. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research report on Tuesday, February 18th.

Anixa Biosciences Trading Up 0.3 %

Shares of ANIX stock opened at $3.16 on Friday. The stock has a 50 day moving average of $2.89 and a two-hundred day moving average of $3.01. Anixa Biosciences has a 12 month low of $2.07 and a 12 month high of $4.20. The company has a market capitalization of $101.74 million, a P/E ratio of -8.10 and a beta of 0.86.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). Sell-side analysts predict that Anixa Biosciences will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Anixa Biosciences news, CEO Amit Kumar purchased 43,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was purchased at an average cost of $2.23 per share, with a total value of $95,890.00. Following the acquisition, the chief executive officer now directly owns 559,925 shares of the company’s stock, valued at approximately $1,248,632.75. This trade represents a 8.32 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The shares were acquired at an average cost of $2.57 per share, with a total value of $25,700.00. Following the completion of the acquisition, the director now directly owns 922,334 shares in the company, valued at approximately $2,370,398.38. This represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 75,289 shares of company stock worth $177,021 in the last 90 days. 25.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Anixa Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in shares of Anixa Biosciences in the 3rd quarter valued at $34,000. Westside Investment Management Inc. increased its stake in shares of Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after buying an additional 21,100 shares during the period. Prosperity Wealth Management Inc. acquired a new stake in shares of Anixa Biosciences in the 4th quarter valued at $54,000. Millennium Management LLC acquired a new stake in shares of Anixa Biosciences in the 4th quarter valued at $26,000. Finally, Jane Street Group LLC acquired a new stake in shares of Anixa Biosciences in the 4th quarter valued at $67,000. 29.13% of the stock is owned by institutional investors and hedge funds.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.